Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

To assess the efficacy and safety of budesonide and formoterol in a single inhaler for maintenance and reliever therapy in asthma compared with maintenance with inhaled corticosteroids (ICS) (alone or ...

Budesonide suspension is still one of the main drugs for the treatment of lobar pneumonia in children. It has a highly effective local anti-inflammatory effect, which can promote the stabilization of ...

A variety of common drugs for asthma, chronic obstructive pulmonary disease (COPD), diabetics, cyanide poisoning, pulmonary fibrosis, etc. such as albuterol, Humulin U-100, cobinamide, interferon-γ, ...

The phase III multi-national study, dubbed ICoN-1 will evaluate the efficacy and safety of Clofazimine Inhalation Suspension when added to guideline-based therapy in adults with refractory ...

FDA has approved budesonide oral suspension to treat patients 11 years of age and older with eosinophilic esophagitis (EoE). The oral therapy, to be sold as Eohilia, will be available by the end ...

Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children from 12 months old to 8 years.

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has received FDA approval to manufacture and market Budesonide Inhalation Suspension, 0.5 mg/2 mL single-dose ampule. The drug is ...

Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children of age 12 months to 8 years.

Hyderabad, Nov 30 (UNI) Hyderabad-based Aurobindo Pharma Limited on Thursday said that its wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US ...